Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 10/20 | 0.69 |
| ▸ | HTR2A | P28223 | 8/20 | 0.69 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.43 |
| ▸ | SCN4A | P35499 | 1/20 | 0.43 |
| ▸ | PIM1 | P11309 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | SCN7A | Q01118 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.34 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.33 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL970777 | 0.82 | HTR2A (1.00) | HTR2CHTR2A | |
| SCHEMBL30104796 | 0.79 | HTR2C (0.62) | HTR2CHTR2AKCNH2 | |
| SCHEMBL6713758 | 0.79 | HTR2C (0.51) | HTR2CHTR2ASCN9ASCN4APIM1 | |
| SCHEMBL4705406 | 0.77 | HTR2A (0.68) | HTR2CHTR2AKCNH2SLC6A2 | |
| SCHEMBL6718716 | 0.75 | HTR2C (0.44) | HTR2CHTR2ASCN9ASCN4APIM1 | |
| SCHEMBL5917403 | 0.74 | HTR2A (0.68) | HTR2CHTR2A | |
| SCHEMBL5917499 | 0.74 | HTR2C (1.00) | HTR2CHTR2A | |
| SCHEMBL4705400 | 0.74 | HTR2A (0.68) | HTR2CHTR2AMAOAKCNH2SLC6A2 | |
| SCHEMBL13226939 | 0.73 | HTR2A (0.62) | HTR2CHTR2AKCNH2 | |
| SCHEMBL13208414 | 0.73 | HTR2A (0.62) | HTR2CHTR2AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1828200-B1 | BI- AND TRICYCLIC SUBSTITUTED PHENYL METHANONES AS GLYCINE TRANSPORTER I (GLYT-1) INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE. | HOFFMANN LA ROCHE (CH) | 2010-02-17 | — | — | EP | disclosed |
| US-7375226-B2 | Bi- and tricyclic substituted phenyl methanones | HOFFMAN-LA ROCHE INC. (US) | 2008-05-20 | — | — | US | disclosed |
| EP-1828200-A1 | BI- AND TRICYCLIC SUBSTITUTED PHENYL METHANONES AS GLYCINE TRANSPORTER I (GLYT-1) INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE. | F. Hoffmann-Roche AG (CH) | 2007-09-05 | — | — | EP | disclosed |
| WO-2006063709-A1 | BI- AND TRICYCLIC SUBSTITUTED PHENYL METHANONES AS GLYCINE TRANSPORTER I (GLYT-1) INHIBITORS FOR THE TREATMENT OF ALZHEIMER’S DISEASE | F.HOFFMANN-LA ROCHE AG (CH) | 2006-06-22 | — | — | WO | disclosed |
| US-20060128713-A1 | (6-Chloro-3,4-dihydro-1H-benzo[4,5]thieno[2,3-c]pyridin-2-yl)-(2-isopropoxy-5-methanesulfonyl-phenyl)-methanone; glyicne transporter 1 (GlyT-1) and N-methyl-D-aspartate (NMDA) receptors inhibitor; psychoses, schizophrenia, attention deficit disorders, Alzheimer's disease; cognition activator | HOFFMANN-LA ROCHE INC. | 2006-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128713-A1 | (6-Chloro-3,4-dihydro-1H-benzo[4,5]thieno[2,3-c]pyridin-2-yl)-(2-isopropoxy-5-methanesulfonyl-phenyl)-methanone; glyicne transporter 1 (GlyT-1) and N-methyl-D-aspartate (NMDA) receptors inhibitor; psychoses, schizophrenia, attention deficit disorders, Alzheimer's disease; cognition activator | GRIN1, GRIA1, GRM1 | HTR2C 160/4885HTR2A 199/4885SCN9A 1671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.